All AbMole products are for research use only, cannot be used for human consumption.
In vitro: Adalimumab blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine. Through its anti-TNF actions, adalimumab reduces concentrations of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, reduces of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, and reduces concentrations of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-1β mRNA, IL-1 receptor antagonist, IL-6).
In vivo: Adalimumab is safe and well tolerated. In healthy adults, the average absolute bioavailability of adalimumab 40 mg administered subcutaneously (s.c.) is 64%. Concentrations in the synovial fluid are 31-96% of those of the serum. Maximum plasma concentrations occur at 131 (± 56) h, and the mean half-life is ∼ 2 weeks (range, 10-20 days). Adalimumab treatment attenuates the Ovalbumin(OVA)-induced increase in serum IgE, TH2 and TH1 derived inflammatory cytokines (IL-4 and IFN-γ, respectively) in bronchoalveolar lavage (BAL) fluid, suppresses recruitment of inflammatory cells in BAL fluid and lung, and inhibits BAL fluid neutrophilia. It also ameliorates goblet cell metaplasia and bronchial fibrosis.
| Cell Experiment | |
|---|---|
| Cell lines | Caco-2 BBE cells |
| Preparation method | T-84 and Caco-2 cells grown on transwell inserts were primed with IFN-γ (2.5 and 5 ng/ml, respectively) for 24 h followed by treatment with TNF-α (5 ng/ml), adalimumab (10 μg/ ml), or both. |
| Concentrations | 10 μg/ ml |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | CD1 mice |
| Formulation | PBS |
| Dosages | 1 ml/100 g b.wt |
| Administration | i.p. |
| CAS Number | 331731-18-1 |
| Storage | Store at -20°C or -70°C. Avoid multiple freeze-thaws. |
| Related TNF Receptor Products |
|---|
| BMS-566394
BMS-566394 is a potent, exceptionally selective inhibitor of TNF-α converting enzyme (TACE). |
| APVO603
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. |
| STAR-0310
STAR-0310 is a novel OX40 antagonistic monoclonal antibody which has a potential best-in-class profile with a high affinity, potential for favorable safety and tolerability profile with low T cell depletion from ADCC or possible on-target cellular toxicity. |
| FS120
FS120 is a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 (4-1BB, TNFRSF9) and OX40 (CD134, TNFRSF4). FS120 has the potential to show activity in "cold" tumors and improve outcomes of existing immunotherapies by simultaneously agonizing CD137 and OX40. |
| ATOR-1015
ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody with enhanced immune activation and tumor-directed activity for improved efficacy and reduced toxicity. ATOR-1015 induces T-cell activation and Treg depletion in vitro. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
